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Abstract
Urine has emerged as an attractive biofluid for the noninvasive detection of prostate cancer (PCa). There is a strong
imperative to discover candidate urinary markers for the clinical diagnosis and prognosis of PCa. The rising flood of various
omics profiles presents immense opportunities for the identification of prospective biomarkers. Here we present a simple
and efficient strategy to derive candidate urine markers for prostate tumor by mining cancer genomic profiles from public
databases. Prostate, bladder and kidney are three major tissues from which cellular matters could be released into urine. To
identify urinary markers specific for PCa, upregulated entities that might be shed in exosomes of bladder cancer and kidney
cancer are first excluded. Through the ontology-based filtering and further assessment, a reduced list of 19 entities
encoding urinary proteins was derived as putative PCa markers. Among them, we have found 10 entities closely associated
with the process of tumor cell growth and development by pathway enrichment analysis. Further, using the 10 entities as
seeds, we have constructed a protein-protein interaction (PPI) subnetwork and suggested a few urine markers as preferred
prognostic markers to monitor the invasion and progression of PCa. Our approach is amenable to discover and prioritize
potential markers present in a variety of body fluids for a spectrum of human diseases.
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Introduction
Prostate cancer (PCa) remains to be the most common
malignancy and the second cause of cancer-related death for men
worldwide[1].Particularlyinthewesternworld,thenumberofmen
diagnosedwith PCahas increased by30% over thelast25 years and
is expected to be doubled by the year of 2030 [2]. PCa is generally
curable when the primary lesion is within its benign state but very
difficult to cure or no longer curable once the tumor has spread to
other distant sites. Therefore, the early detection is essential for the
successful clinical treatment of PCa. Currently, the combination of
DRE (digital rectal exam) and the PSA (prostate-specific antigen)
blood test is commonly used in screening test to detect PCa in the
absence of symptoms. Unfortunately, it is well recognized that the
usefulness of PSA suffers from its low specificity and its low positive
predictive value in early PCa detection. For example, it has been
found that the upper cut-off of the PSA reference level at 4.0 ng/ml
fails to detect a large number of PCa and many men with PSA
values ,4.0 ng/ml actually have PCa [3]. Moreover, it has been
demonstrated that PSA can be secreted from other cancerous cells
into the bloodstream as well [4]. Hence, there is a clear need to
identify putative molecular signaturesthat canfacilitatetheaccurate
and non-invasive clinical PCa detection.
Urine represents an amenable and appealing body fluid for the
early detection of PCa [5]. First, urine can be used to detect the
presence of PCa because secreted prostatic products or exfoliated
cancerous cells are released directly into the genitourinary tract.
Second, urine can be easily collected in large amounts noninva-
sively and repeatedly, rendering it as an attractive material for the
analysis of prostate malignancy. To date, a number of urine
biomarkers such as GSTP-1 (glutathione-S-transferase P1), DD3
(prostate cancer antigen 3, PCA3) and TB-15 (thymosin b15) etc.
have been proposed as potential diagnostic agents for early PCa
detection [6]. Moreover, with the recently developed sophisticated
mass-spectrometry (MS) technology, it becomes possible to detect
certain endogenous metabolites in urine for the early diagnosis of
PCa. For instance, Sreekumar et al. [7] have identified Sarcosine
(N-methylglycine) as a key metabolite in urine that could be
potentially used as a marker for PCa malignancy. Although
promising, there are still few studies assessing urine markers for
PCa detection and there are only a few candidate urine markers
are under consideration for future clinical development. Further,
no single marker is adequate for the accurate detection of PCa
owing to the complexity and heterogeneity of the disease. Hence, it
is clear that a panel of urine markers is required for the successful
diagnosis of PCa.
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from high-throughput ‘Omics’ technologies such as microarrays
has provided unprecedented opportunities for researchers to
uncover biomarkers and phenotypic pathways of clinical impor-
tance [8]. For instance, Kim et al. have reported the mining of
public gene profiles from CGAP and GEO database to identify
seven putative markers for lung cancer [9]. Analogously, we have
successfully identified lists of blood-borne markers for six common
human cancer types through a combined mining strategy in the
Oncomine microarray database and a pathway knowledgebase.
Using a filter-based approach and comparison analysis, we have
retrieved disease-specific blood-based markers for each of the
tumor types and common markers shared between different
tumors. Notably, a large portion of the retrieved genomic-based
markers have been literature-confirmed to be associated with the
phenotypic pathways of tumor progression and invasiveness. Such
findings would certainly be very useful to delineate potential
targets with regards to the diagnosis, prognosis and pathogenesis of
human solid tumors.
Here we present an integrative mining approach to analyze
public genomic profiles for the discovery of potential urine
markers for PCa detection. Our strategy has been developed in the
way that a vast body of cancer genomic profiles can be analyzed in
the context of other biological data such as gene ontology,
metabolic pathways and gene-gene/protein-protein interaction
(PPI) networks (see Figure 1). To identify disease-specific markers
for PCa, we have retrieved upregulated genes in PCa, bladder
cancer and kidney cancer from public cancer genomic databases.
We were mining for upregulated genes as PCa markers here
mainly because one of the prevailing hypotheses is that the most
promising biomarkers for clinical use will be those upregulated
genes or their protein products. However, we recognize that this
might not be generally true and thereby we don’t rule out the
possibility that downregulated genes could be interesting candidate
markers too. Other researchers could choose to mine downreg-
ulated genes for their specific purpose by applying the similar
strategy as in this work. These upregulated genes were then filtered
through a collection of ontology terms indicating the presence in
urine and Ingenuity Knowledgebase. A comparison analysis was
performed across prostate, bladder and kidney and only those
entities unique to prostate were kept in the list as potential urinary
markers for PCa. This is because entities present in bladder cancer
and kidney cancer may interfere with the detection of PCa shed in
human urinary system. Finally, the putative urine markers for PCa
were analyzed and prioritized within metabolic pathways and
protein-protein interaction networks. Our strategy highlights the
significance of combining a variety of biological data to derive
putative markers present in body fluids with disease specificity to
detect common and lethal types of human cancers.
Materials and Methods
The focus of our analysis approach is to retrieve putative
markers present in urine for the specific detection of PCa.
Therefore, we need to retrieve and filter genes significantly
upregulated in PCa, encoding urinary proteins, to a manageable
gene list. The choice of microarray platform or database, statistical
cut-off criteria, and controlled ontology terms (Gene Ontology
terms) in the mining strategy is variable, depending on the
particular interest and requirement of the user.
Microarray data preparation and analysis
In brief, for each of the three tumor types (PCa, bladder cancer
and renal cancer), MeSH terms (prostate cancer, prostatic cancer;
bladder cancer; kidney cancer, renal cancer) were used to search
and obtain microarray experiments characterizing these disease
conditions from two popular cancer genomic databases, Oncomine
database [10] and ArrayExpress database [11]. Oncomine and
ArrayExpress were chosen because they are two of the largest public
cancer microarray repositories. Particularly, Oncomine has incor-
porated 534 independent microarray datasets, which span 35
cancer types. It unifies a large compendium of other published
cancermicroarraydataaswellincludingGeneExpressionOmnibus
(GEO) and Stanford Microarray Database (SMD). ArrayExpress
stores well-annotated raw and normalized cancer microarray data
from morethan 300 studies. The advantage of using Oncomine and
ArrayExpress is that medical researchers could easily perform
differential expression analyses comparing most major types of
cancer with their respective normal or benign tissues. Those
microarray experiments comparing cancer vs. normal including
malignant vs. benign conditions measured in equivalent tissues in
same experiments were retained. We have chosen a relative
stringent FDR (false discovery rate) value cut-off of 0.05 [12] in the
analysis process, and only those overexpressed genes with FDR
value less than 0.05 are kept in the final list. Overexpressed genes in
OncomineandArrayExpresswerecollectedbyusingthe sameFDR
cut-offvalue.Inaddition,acustomaryfoldchangethreshold2.0was
also applied to retain those significantly overexpressed genes in the
list. The redundant genes were resolved from the list. By
comparison analysis across the upregulated genes of three tumor
types using a C# program (see File S1), only those genes
specifically upregulated in PCa were retrieved for further analysis.
Figure 1. Workflow of integrative mining from public cancer
genomic profiles for discovery of putative urinary marker for
the specific detection of PCa. In the comparison pie graphs, ‘‘B’’
represents for bladder, ‘‘K’’ represents for kidney and ‘‘P’’ represents for
prostate.
doi:10.1371/journal.pone.0028552.g001
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Functional annotation (Gene Ontology assignment) for the
retrieved overexpressed genes was conducted by using the DAVID
system [13]. Next, a set of controlled GO terms implying the
presence in urinary proteome were chosen according to the GO
clustering analysis of 1273 urinary proteins (see Figure 2)
collected from MAPU urinary proteome database [14]. The GO
clustering analysis was performed within DAVID system and
could be used to measure the GO term appearing frequencies
among the urinary proteins. Specifically, these controlled GO
terms and their appearing frequencies are: Extracelluar region
part: 34.8%; Response to stimulus: 25.5%; Cell adhesion: 13.2%;
Calcium ion binding: 11.3%; Cell communication: 5.5%; Amine
metabolic process: 1.9%. These controlled GO terms are enriched
and overrepresented in the urinary proteome through the study of
GO clustering. Further, the retrieved putative urine markers were
consulted in Sys-BodyFluid database [15], MAPU proteome
database and Ingenuity Knowledgebase [16] to confirm their
presence in urine. Entities that are not present in urine were
removed from the list. These databases represent the three most
comprehensive public body fluid proteomes and contain over
10,000 proteins with detailed annotations. Researchers could
easily download and analyze protein targets present in various
body fluids from these on-line databases.
Pathway enrichment analysis
The derived list of putative urine markers was then subjected to
pathway enrichment analysis by importing them to a few PPI
(protein-protein interaction) databases including Pfam [17],
InterPro [18], Ingenuity Knowledgebase and the KEGG Knowl-
edgebase [19]. These PPI databases were chosen because they are
widely used as reference knowledgebase towards practical
applications with network or pathway-based views of proteins,
diseases and drugs. Moreover, the millions of pathway interactions
storing in these knowledgebase were acquired by curation of
scientific publications covering information on genes or proteins.
The 19 entities were first imported as seeds to identify
overrepresented biological functions and signaling pathways.
Entities with direct physical interactions and co-expression
evidenced by literatures were identified and used to construct
PPI network. Particularly, those entities associated with the tumor
cell growth, development and proliferation were used as seeds to
construct a PPI subnetwork related to the invasion and metastasis
of PCa. Subnetworks were constructed such that the genes
(proteins) were nodes, with edges between genes indicating the
direction and indirect biological interactions between entities.
Literature Review of the Candidate Entities
Further analysis and assessment of the resulting putative
markers was performed retrospectively using GeneCards (www.
genecards.org), a curated database that finds links and cited
articles to genes/proteins. The entities obtained were checked by
carefully reading the associated literature references or original
publications. The accuracy of the findings is assessed using control
entities, selected as candidate molecules by other studies or well-
known and clinically useful targets for PCa.
Results
The integrative mining approach assembling Oncomine,
ArrayExpress and GEO databases has yielded 5 microarray
datasets for bladder, 8 microarray datasets for renal and 15
microarray datasets for prostate (cancer vs. normal including
malignant vs. benign condition) by using specific MeSH terms for
each tissue type. The mining of these datasets by a relative
stringent FDR value cut-off of 0.05 has yielded between 1,112
(renal), 11,191 (bladder) and 13,595 (prostate) overexpressed genes
for the three cancer types. Next, a comparison analysis across the
three tumor types has yielded a list of 3964 uniquely upregulated
genes in PCa, a list of 2364 uniquely upregulated genes in bladder
and a list of 51 uniquely upregulated genes in renal. Sequentially,
the 3964 uniquely upregulated genes in PCa were filtered by the
seven controlled GO terms to yield a list of 19 putative markers
which were further consulted by Sys-BodyFluid database and
MAPU proteome database to assess their presence in urine.
Finally, the list of 19 urinary proteins were subjected to pathway
enrichment analysis within a few most popular PPI databases
including Pfam, InterPro, Ingenuity Knowledgebase and KEGG.
All the 19 entities were found to be connected as a network
together with another 10 entities based on co-expression, shared
protein domains, co-localization and protein physical interaction
relationships [20,21] (see Figure 3). Sharing a protein domain
implies that two entities may have very similar functions, but
doesn’t guarantee that the two entities are connected in the same
pathway; co-expression implies that two entities share similar
expression pattern; co-localization implies that two entities are
expressed in the same tissues or identified in the same cellular
location. Within the network, we have found that RBP4 (retinol
binding protein 4, plasma), CFH (complement factor H), ITIH4
(inter-alpha (globulin) inhibitor H4) and FTL (ferritin, light
polypeptide) are linked due to co-localization; APOD (apolipo-
protein D), RBP4 and CRABP1 (cellular retinoic acid binding
protein 1) are found to share protein domains according to
INTERPRO and PFAM databases. In addition, we have found
that CYP2B6 (cytochrome P450, family 2, subfamily B, polypep-
tide 6) connects with four putative markers because of co-
localization; C6 (complement component 6) connects to RBP4 and
ITIH4 by co-localization; C6 connects to CFH and RECK
(reversion-inducing-cysteine-rich protein with kazal motifs) by
sharing same protein domains; TTR (transthyretin) has physical
interaction with RBP4, CFH and CLU (clusterin) genes;
OSBPL1A (oxysterol binding protein-like 1A) co-localizes with
Figure 2. Pie-chart of GO term appearing frequencies among
the urinary proteins by clustering analysis of 1273 urinary
proteins performed within DAVID system.
doi:10.1371/journal.pone.0028552.g002
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CD70 (CD70 molecule) connects with the candidate marker
CD27 (CD27 molecule) by co-localization and physical interac-
tion; CD70 shares the same protein domain with C1QTNF3 (C1q
and tumor necrosis factor related protein 3). Furthermore, we
have found these marker proteins are largely associated with a few
metabolic pathways such as N-glycan biosynthesis, acute phase
response signaling and xenobiotic metabolism signaling etc.
Interestingly, we have found that 10 out the 19 urinary markers
are closely associated with tumor cell development, growth and
proliferation pathway (see Figure 4).
Identification of Putative Urine Markers for PCa Detection
As positive controls, we have highlighted below a few very
promising urine marker derived from our study that have also
been evidenced by precedent literatures as urinary targets. The
five ‘positive control’ entities were chosen according to their fold
change values in the order of LGALS3 (lectin, galactoside-binding,
soluble 3), CFB (complement factor B), APOD, RECK and PECAM1
(platelet/endothelial cell adhesion molecule). These entities stand a
good chance of being clinically useful markers as they are most
upregulated and their protein products are likely to be overpro-
duced in cancerous cells. We want to remind the reader that the
study was strived to identify putative urine markers from genomic
profiles thereby it is not sufficient to state that: 1) the encoding
product of the gene is present or truly upregulated at the protein
level; 2) it is really localized at the desired location (excreted into
urine) or normally functioning. Hence, the targets derived from
the genomic profiling studies need to be further validated at the
protein level through various experimental approaches.
Lectin, galactoside-binding, soluble, 3 (LGALS3/GAL3)
One interesting putative urine marker that we have retrieved
from the mining study is LGALS3, which encodes a member of the
galectin family of carbohydrate binding proteins. This protein has
been implicated in numerous cellular functions including cell
proliferation, apoptosis, angiogenesis, tumor progression and
metastasis. In fact, a recent study [22] has suggested that LGALS3
encoding protein, galectin-3, is cleaved during the progression of
PCa and might be associated with the progression and metastasis
of PCa cells; Sardana et al [23] have suggested galectin-3 as one of
the candidate marker proteins shed and secreted by prostate tumor
cells. Remarkably, we have found that LGALS3 has the largest fold
change value of 4.121 in cancerous condition compared to normal
condition (see Table 1) among the 19 entities, rendering it a
highly interesting molecule for the diagnosis and prognosis of PCa.
Complement factor B (CFB)
CFB, encodes complement factor B, a component of the
alternative pathway of complement activation. Factor B circulates
in the blood as a single chain polypeptide. In our study, CFB has
been retrieved as a potential marker upregulated in urine (fold
change, 3.231; rank as No. 2 among 19 entities) for the diagnosis
of PCa. Indeed, there have been various studies confirming the
Figure 3. Identification of gene network consisting of 19 putative urine markers (Cytoscape/Genemania). Nineteen putative marker
genes are represented as red nodes and the other highly relevant genes are in white. Co-expressed genes are linked by blue lines, genes with same
protein domains are linked by green lines, co-localization relationships are described as pink lines, and physical interaction connections are linked by
black lines.
doi:10.1371/journal.pone.0028552.g003
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have identified Complement factor B preproprotein as the third
most abundant protein in the serum sample of PCa patients. This
might implicate the close association of CFB with the pathogenesis
of PCa. Therefore, the usefulness of CFB in the urine detection of
PCa is well worth of further investigation.
Apolipoprotein D (APOD/Apo-D)
APOD, encodes a component of high density glycoprotein which
is closely associated with cholesterol acyltransferase, an enzyme
involved in lipoprotein metabolism. APOD is also involved in the
transport and binding of bilin. In our study, APOD has been
retrieved as a potential marker upregulated in urine (fold change,
2.803; rank as No. 3 among 19 entities) for the diagnosis of PCa.
Indeed, there have been various clinical studies confirming the
presence of APOD in urine and its role in disease detection. For
example, Kentsis et al. have discovered APOD as one of the putative
urine markers for the clinical diagnosis of acute appendicitis [24].
The protein abundance level of APOD in urine and its correlation
with severity of appendicitis are validated by targeted mass
spectrometry. Furthermore, Aspinall et al. has found that elevated
Apo-D level is closely associated with the advancement of PCa [25].
Put together, APOD could be a very promising urine marker for the
clinical detection and prognosis of human PCa.
Reversion-inducing-cysteine-rich protein with kazal
motifs (RECK)
Extracelluar matrix remodeling is a prerequisite in tumor
invasion and often leads to the overexpression of matrix
metalloproteinases (MMPs). RECK is an inhibitor of MMPs by
negatively regulating MMP-2, MMP-9 and MMP14/MT1-MMP
activity [26]. Regarding PCa, the role of RECK has not yet been
clarified. Interestingly, we have retrieved RECK as a potential
marker upregulated in urine of PCa patients (fold change, 2.569;
rank as No. 4 among 19 entities). This might be a reflection of the
interrelationship of RECK with MMP-2 and MMP-9 along the
metastasis process of PCa. Thereby, the potential of RECK in the
diagnosis/prognosis of PCa has emerged from our study.
Platelet endothelial cell adhesion molecule (PECAM1/
CD31)
PECAM1 is mostly found on the surface of platelets, monocytes,
neutrophils, and some types of T-cells. PECAM1 is known for its
key role in removing aged neutrophils from the body [27]. In an
early study, Huss et al. [28] have found that PECAM1 is associated
with the early event of angiogenesis and the initiation and
progression PCa. This is consistent with our study that PECAM1
functions as a hub entity in the network of PCa progression and
metastasis according to its centrality in the network. We have
Figure 4. Identification of ‘focused’ protein-protein interaction (PPI) network that may lead to PCa progression and metastasis.
Gene products are represented as nodes and biological relationships (direct and indirect) are described as lines (protein–protein interactions) and
dashed lines (regulations of bindings, inhibitions, proteolysis, phosphorylation or modifications). The hub entities that are synergistically regulated in
this subnetwork are highlighted as red color including CD27, CLU, LGALS3, APOD, MGAT5, CFB, RBP4, ITIH4, PECAM1 and RECK. Their subcellular
locations are not indicated in the figure.
doi:10.1371/journal.pone.0028552.g004
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PCa patients (fold change, 2.404; rank as No. 5 among 19 entities).
Collectively, PECAM1 might be explored as a potential urine
marker for the diagnosis/prognosis of PCa.
Discussion
In the present study, we have proposed an integrative mining
approach for the identification of putative urine markers specific
for PCa detection derived from public genomic profiles. The
uniqueness of our approach is that genes specifically overexpressed
in PCa were first identified by comparison analysis between PCa,
bladder cancer and renal cancer, the three major malignancies in
human urinary system. Only in this way, urine markers that are
likely to be highly discerning for PCa can be identified by
excluding those urinary proteins released in the disease conditions
of bladder tumor and renal tumor. The set of controlled GO terms
enriched in urine proteome was used as ontology filters in our
study to identify genes encoding putative urinary proteins. Indeed,
this ontology-based filtering strategy has been frequently used in
the mining of functional genomic profiles to derive targets with
biological significance. Moreover, to ascertain their presence in
urine, these putative PCa urinary proteins were further consulted
in databases warehousing urinary proteome data. The pathway
enrichment analysis was also adopted in our strategy to investigate
the association of the derived entities with the pathogenesis of
human cancer. We believe that the assembling of functional
genomic data, ontology-based filters, urinary proteome databases
and pathway enrichment analysis could be well suited in the
discovery of candidate biomarkers in biofluids for the detection of
PCa as well as for many other human diseases.
One interesting finding from our study is that a large portion of
the derived entities (9 out of 19 entities, see Table 1) are present
in both urine and blood. This is probably because the quantity of
the urine excretion bears a direct proportion of the blood. These
markers might be secreted to blood from cancerous cells first and
then excreted into urine. Therefore, these entities might be used as
candidate markers for PCa screening detectable in both fluids.
Another interesting finding from the pathway enrichment analysis
is that numerous markers derived from the study are involved in
the body’s innate immune response system. For instance, CFB,
CFH and FTL are found to be associated with the acute-phase
signaling pathway, which consists of a large number of proteins
produced in response to body inflammation. Hence, these urinary
proteins could serve as PCa markers to inform disease progression
or disease management with regards to the host defense response
of the patients, during which the innate immune system is
triggered to attack the tumor cells. Moreover, MGAT5, identified
as a urine marker for PCa detection, was found to be involved in
N-glycan biosynthesis pathway which is crucial in the adhesive or
migratory behavior of cancerous cells. Consequently, MGAT5
could be further investigated as a prognostic marker for PCa
invasion and progression. Intriguingly, we have found a few
entities (CRABP1, FTL, MGAT5 and SELEBP1) as putative urine
markers annotated by GO terms indicating their intracellular
location. This could be accounted by the secretion of intracellular
proteins inside small-membrane vesicles named as exosomes
released into urine from prostate. Furthermore, cancerous cells
undergoing apoptosis are likely to release intracellular matter into
urine.
Another merit of our integrative mining approach is the ability
to identify ‘focused’ protein interaction networks consisting of
derived entities associated with pathogenesis of human cancer. It
has been recognized that genes/proteins with potentials as
diagnostic or therapeutic targets are more likely to function as a
cooperative group or network in human cancer [29]. As an
Table 1. Identified urinary markers for the unique detection of prostate tumor.
Symbol Gene name Location Family Urine Blood Fold-change P value
APOD apolipoprotein D Extracellular space transporter NN2.803 2.00E-03
C1QTNF3 C1q and tumor necrosis factor related protein 3 Extracellular Space other N 1.100 2.50E-02
CD27 CD27 molecule Plasma Membrane Transmembrane
receptor
NN1.183 8.19E-04
CFB complement factor B Extracellular Space peptidase N 3.231 4.00E-03
CFH complement factor H Extracellular Space other NN1.381 1.00E-03
CLU clusterin Extracellular Space other N 1.638 1.50E-02
CRABP1 cellular retinoic acid binding protein 1 Cytoplasm transporter N 1.477 1.20E-02
DDAH2 dimethylarginine dimethylaminohydrolase 2 Cytoplasm enzyme N 1.152 4.80E-02
FTL ferritin, light polypeptide Cytoplasm other N 1.718 3.00E-03
IGSF8 immunoglobulin superfamily, member 8 Plasma Membrane other NN1.358 6.00E-03
ITIH4 inter-alpha (globulin) inhibitor H4 Extracellular Space other NN1.215 2.40E-02
LGALS3 lectin, galactoside-binding, soluble, 3 Extracellular Space other NN4.121 5.90E-04
LYZ lysozyme Extracellular Space enzyme NN2.093 4.00E-03
MGAT5 hypothetical LOC151162 Cytoplasm enzyme NN1.112 3.00E-03
PECAM1 platelet/endothelial cell adhesion molecule Plasma Membrane other NN2.404 1.01E-04
RBP4 retinol binding protein 4, plasma Extracellular Space transporter N 1.872 2.70E-02
RECK reversion-inducing-cysteine-rich protein Plasma Membrane other N 2.569 4.60E-02
SELENBP1 selenium binding protein 1 Cytoplasm other N 1.327 1.20E-02
SLIT2 slit homolog 2 (Drosophila) Extracellular Space other N 1.848 3.60E-02
Black circle represents the presence in the biofluid.
doi:10.1371/journal.pone.0028552.t001
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in the process of tumor cell growth, development and proliferation
using pathway enrichment analysis. Using these entities as seeds,
we have constructed a protein-protein interaction subnetwork
which might lead to PCa progression and metastasis. Among the
ten entities, we have found that LGALS3, PECAM1, MGAT5,
RECK and CLU function as ‘hub’ entities with high connectivity (a
large number of interactions with other entities) in the network. To
prioritize the ‘highly influential’ entities in the PCa network, we
have applied the concept of graph theory [30] to calculate the
betweeness centrality and closeness centrality for each entity. The
formulas to calculate the betweeness centrality and closeness
centrality are as below,
For a graph G:=(V, E) with n vertices, the betweenness
centrality CB(v) for vertex v is:
CB(v)~deg(v) ð1Þ
The closeness centrality is defined as the mean geodesic distance
(i.e., the shortest path) between a vertex v and all other vertices
reachable from it,
CC(v)~
P
t[V\v
dG(v,t)
n{1
ð2Þ
By calculating centrality score for each entity in the PCa network
(see Figure 5), we have found that LGALS3, PECAM1 and
MGAT5 appear to be the three most ‘influential’ entities in the
network with the highest centrality scores. They might be used as
prioritized prognostic agents for the detection of PCa invasion and
progression. Therefore, strategies could be formulated in the
process of PCa treatment to monitor the synergic expression of
these entities in urine as strong indicators of therapeutic response
and outcome. Moreover, understanding of such networks with
related genetic changes which promote tumorigenesis will improve
PCa detection and potentially identify novel points of therapeutic
intervention.
We recognize several caveats in our mining strategy. First, we
make the assumption in the approach that the expression level of a
gene is a true reflection of its encoding protein level in the urine.
This assumption doesn’t always hold true as we mentioned earlier
in the paper. Second, the study is limited by the quantity and
quality of microarray datasets for the three tumor types.
Therefore, the specificity of the PCa urine markers in our study
is subject to the availability of the microarray data for each disease.
Nevertheless, we believe that our strategy has captured the most
important features in the mining of cancer genomics profiles for
the discovery of putative markers in body fluids. Further, our
strategy is simple to implement for experimentalist and could be
used to provide interesting candidate markers for the discovery of
clinically useful markers through targeted proteomic analysis.
Conclusion
We have described herein an integrative and experimentalist-
friendly approach to derive potential urine markers for the specific
detection of PCa by assembling of cancer gene expression profiles,
ontology-based filters, urinary proteome databases and pathway
knowledgebase. The application of this strategy has led to the
identification of 19 upregulated entities encoding putative urinary
protein markers for noninvasive PCa detection. To the best of our
knowledge, our study is the first to identify those putative urine
markers specific for PCa by comparison analysis across three
major tissue types within human urinary system. In addition, our
approach offers the advantage of prioritizing candidate markers to
detect the invasion and progression of PCa by constructing
Figure 5. Betweenness centrality score and closeness centrality score for the 10 entities involved in the network of PCa progression
and metastasis. Betweeness centrality score was denoted as BC and closeness centrality score was denoted as CC: LGALS3 (BC, 6.00; CC, 3.56);
PECAM1 (BC, 4.00; CC, 2.56); CD27 (BC, 3.00; CC, 0.04); RECK (BC, 3.00; CC, 0.00); MGAT5 (BC, 4.00; CC, 2.56); CLU (BC, 2.00; CC, 0.24); ITIH4 (BC, 2.00; CC,
0.04); RBP4 (BC, 1.00; CC, 0.12); APOD (BC, 1.00; CC, 0.00); CFB (BC, 1.00; CC, 0.00).
doi:10.1371/journal.pone.0028552.g005
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ment analysis. Moreover, these retrieved entities could be used to
extract biological insights for dissecting the pathogenesis of human
PCa. In general, this integrative mining approach could be
broadly applied to discover candidate markers present in body
fluids for the diagnosis or prognosis of many other human diseases.
Supporting Information
File S1 C# source code and its GUI program to
compare entities derived from different tissue types
(use CSV files from Microsoft Excel program as inputs).
(RAR)
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